Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
33.51
-2.39 (-6.66%)
Aug 13, 2025, 4:00 PM - Market closed
Monopar Therapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Monopar Therapeutics stock ranges from a low of $40 to a high of $76. The average analyst price target of $62 forecasts a 85.02% increase in the stock price over the next year.
Price Target: $62.00 (+85.02%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +79.05% | Aug 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $74 | Buy | Initiates | $74 | +120.83% | Jul 7, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +79.05% | Jun 23, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +19.37% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
969.00K
EPS This Year
-2.15
from -4.11
EPS Next Year
-3.57
from -2.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 4.0M | 44.0M | ||
| Avg | n/a | 969,000 | 19.9M | ||
| Low | n/a | n/a | 7.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 4,440.2% | ||
| Avg | - | - | 1,955.4% | ||
| Low | - | - | 646.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.74 | -2.00 | 0.63 | ||
| Avg | -2.15 | -3.57 | -0.47 | ||
| Low | -2.51 | -5.89 | -1.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.